Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-01-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团十届三次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a short announcement of a supervisory board meeting resolution by Kunming Pharmaceutical Group Co., Ltd. It reports the approval of a proposal related to estimated daily related-party transactions with the controlling shareholder for 2022. The document is brief (464 characters) and does not contain financial statements or detailed financial data. It is an official announcement of a board/committee decision rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2022-01-27 Chinese
昆药集团关于公司2022年与控股股东日常关联交易预估的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's estimated daily related party transactions with its controlling shareholder for the year 2022. It includes information on the approval procedures, estimated and actual transaction amounts for the previous year, descriptions of related parties, and the impact of these transactions on the company. The document is not a financial report, audit report, or earnings release, but rather a regulatory announcement about related party transactions. It does not contain financial statements or comprehensive financial analysis but focuses on disclosure of related party dealings and compliance with governance rules. This fits the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-27 Chinese
昆药集团十届三次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the results of a board meeting held on January 27, 2022, including voting outcomes on a specific agenda item related to estimated daily related-party transactions with the controlling shareholder. The document is short (480 characters) and focuses on board decisions rather than financial results or reports. It does not contain financial statements or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors.
2022-01-27 Chinese
昆药集团独立董事关于公司十届三次董事会相关事项的事前认可及独立意见
Board/Management Information Classification · 95% confidence The document contains independent directors' opinions and approvals related to the company's board meeting matters, specifically regarding the 2022 estimated daily related-party transactions with the controlling shareholder. It references compliance with governance guidelines and stock exchange listing rules. The content is focused on board-level approvals and independent director opinions rather than financial results, audit reports, or shareholder voting outcomes. The document is relatively short (818 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results but rather independent directors' opinions on board matters. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2022-01-27 Chinese
昆药集团关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It details the amounts, types of financial products, risk controls, approvals by the board and shareholders, and the impact on the company. The document is a regulatory announcement about the company's capital management activities, specifically the use of idle raised funds for cash management through financial products. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement since it contains substantive information about the transaction and approvals. It is not a call transcript, earnings release, or management report. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage related to raised funds and financial product investments. The document length (5598 characters) and detailed content support this classification with high confidence.
2022-01-04 Chinese
昆药集团关于参与投资基金暨关联交易事项的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding its participation in an investment fund and related party transactions. It includes extensive information about the investment structure, related parties, fund management, investment risks, and legal agreements. The document is lengthy (15,000 characters) and contains substantive details about the transaction, investment amounts, parties involved, and risk disclosures. It is not a financial report like an annual or interim report, nor is it a simple announcement of voting results or a proxy statement. It is a regulatory announcement about a capital investment and related party transaction, which fits best under the category of Capital/Financing Update (CAP). The document does not fit the criteria for other categories such as M&A, Board changes, or Earnings Release. Therefore, the most appropriate classification is CAP with high confidence.
2021-12-14 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.